Esperion Reports Second Quarter 2023 Financial Results : vim

– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for...

Related Keywords

United States , American , Tiffany Aldrich , Alexis Callahan , Sheldon Koenig , Stephenj Nicholls , Kausikk Ray , American Diabetes Association , Exchange Commission , European Medicines Agency , Drug Administration , Twitter , Endocrine Society Meeting , Journal Of The American Medical Association , European Society Of Cardiology , Product Revenue Grew , Prescription Equivalents Grew , Brand Prescriptions Grew , Submitted Applications , Expanded Indications , Label Changes Expected , Presented New , Bempedoic Acid , Primary Prevention Population , Increasing Addressable Market , Chief Executive Officer , American Medical Association , Supplemental New Drug Applications , Scientific Sessions , Cholesterol Treatment Trialist , European Society , Clear Outcomes Total Events Analysis , Clear Outcomes Analysis , Glycaemic Status , Prescribing Information , Contact Information , Markets ,